|
Adherence history:
| | | | | |
|
poor at least once vs optimal
|
2.14
|
(1.45, 3.14)
|
2.18
|
(1.47, 3.22)
|
<0.001
|
|
non-response at least once vs optimal
|
2.16
|
(1.29, 3.52)
|
2.09
|
(1.22, 3.40)
|
<0.001
|
|
missing at least once vs optimal
|
3.46
|
(2.07, 5.54)
|
3.65
|
(2.15, 5.92)
|
0.005
|
|
Pre-ART WHO disease stage
| | | | | |
|
stage 2
|
1(ref)
| |
1(ref)
| |
0.51
|
|
stage 3
|
1.67
|
(0.99, 3.03)
|
1.39
|
(0.82, 2.55)
| |
|
stage 4
|
1.61
|
(0.88, 3.08)
|
1.28
|
(0.68, 2.48)
| |
|
Pre ART CD4 cell count
| | | | | |
|
0-49
|
3.61
|
(1.88, 7.85)
|
3.43
|
(1.74, 7.62)
| |
|
50-99
|
2.75
|
(1.36, 6.14)
|
2.62
|
(1.28, 5.90)
| |
|
100-149
|
2.49
|
(1.20, 5.63)
|
2.45
|
(1.18, 5.57)
| |
|
150-199
|
1(ref)
| |
1(ref)
| |
0.01
|
|
Pre-ART Body mass index
| | | | | |
|
<20
|
1.63
|
(1.12, 2.38)
|
1.33
|
(0.90, 1.96)
| |
|
20-27
|
1(ref)
| |
1(ref)
| |
0.35
|
|
>27
|
0.98
|
(0.43, 1.93)
|
1.07
|
(0.46,2.15)
| |
|
Age at ART initiation groups
| | | | | |
|
18-35
|
1(ref)
| |
1(ref)
| |
0.07
|
|
35-50
|
0.72
|
(0.49, 1.05)
|
0.83
|
(0.56, 1.24)
| |
|
50+
|
1.45
|
(0.74, 2.63)
|
1.74
|
(0.87, 3.21)
| |
|
Sex
| | | | | |
|
Female vs Male
|
0.62
|
(0.43, 0.90)
|
0.72
|
(0.49, 1.06)
|
0.10
|
|
Time since ART initiation in years
| | | | | |
|
≤2
|
1(ref)
| |
1(ref)
| |
0.13
|
|
2-3
|
1.65
|
(0.98, 2.84)
|
1.66
|
(0.98, 2.86)
| |
|
3-4
|
1.10
|
(0.61, 1.99)
|
1.10
|
(0.61, 1.98)
| |
|
4-5
|
1.64
|
(0.96, 2.86)
|
1.56
|
(0.90, 2.74)
| |
|
>5
|
0.91
|
(0.38, 1.96)
|
0.80
|
(0.33, 1.73)
| |
